1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

Regulators Promote Early Process Understanding As Key To Success In Cell Therapy Manufacturing

 
• By Joanne S. Eglovitch

US and Canadian regulators espouse the need for early – and deep – knowledge of cell and gene therapy products as they progress through the pipeline to commercialization. Not doing so compromises product quality, and increases risks to patients.

Cancer Cells

Health regulators advise companies developing cell and gene therapy products to gather as much information early on in product development as possible and to build on this knowledge as these therapies progress through the pipeline from research to commercialization. Having this information early on leads to high-quality, consistent products that can be correlated to safety and efficacy.

Regulators discussed some of the complexities involved in manufacturing cell and gene therapy products and how to surmount these challenges...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

New US FDA Program Encouraging Domestic Manufacturing May Be ‘Very Selective’

 
• By Sarah Karlin-Smith

Pharmaceutical manufacturers encouraged the FDA to consider including expansions and modifications of existing US drug facilities in the PreCheck program.

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

 
• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

Homework Avoidance: US FDA’s Upfront Effort For CMC Pilot Dissuades Participation

 
• By Bridget Silverman

The clarity on quality topics provided by the CMC Readiness Pilot (CDRP) is worth the work of preparing a comprehensive development review and multiple meetings, participants from Intellia, Bicycle Therapeutics and Bristol Myers Squibb said during a Duke Margolis meeting.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 
• By Neena Brizmohun

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

More from Compliance

Homework Avoidance: US FDA’s Upfront Effort For CMC Pilot Dissuades Participation

 
• By Bridget Silverman

The clarity on quality topics provided by the CMC Readiness Pilot (CDRP) is worth the work of preparing a comprehensive development review and multiple meetings, participants from Intellia, Bicycle Therapeutics and Bristol Myers Squibb said during a Duke Margolis meeting.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 
• By Neena Brizmohun

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

US Confirms 15% Tariff On Japanese Drugs, But Confusion Lingers

 
• By Lisa Takagi

After tough negotiations which won the country a lower US levy on pharmaceuticals, there still appears to be some confusion within the Japanese government following President Trump's latest announcement on global pharma tariffs.